NASDAQ$NUWE
Nuwellis Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Nuwellis reported a revenue decrease of 5% year-over-year, with growth in the Heart Failure segment offset by declines in Pediatrics and Critical Care. Gross margin increased by 120 basis points, and the company highlighted clinical evidence supporting its Aquadex therapy.
Nuwellis, Inc. reported first quarter 2023 financial results with revenue of $1.8 million, a 5% decrease compared to the prior-year period. The heart failure segment saw growth, but pediatrics and critical care declined. The company had cash, cash equivalents, and marketable securities of $12.1 million and no debt as of March 31, 2023.
- Revenue for Q1 2023 was $1.8 million, a 5% decrease year-over-year.
- Heart Failure segment revenue increased by approximately 21% compared to the same period last year.
- Pediatrics and Critical Care segments declined by approximately 28% and 4%, respectively.
- Gross margin increased to 58.4%, a 120 basis point increase from the prior-year period.
Headline financials
Revenue & EPS history
Nuwellis · Revenue · Quarterly
$1.83M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-5.5%
Avg return
Earnings day
-10.5%
Avg return
5 days after
-18.5%
Avg return
30 days after
28%
15 / 54 earnings
Positive
+51.9%
Q1 2024
Best reaction
-29.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -5.0% | -86.3% | |
| Q4 2025 | +2.4% | -2.3% | -16.3% | |
| Q3 2025 | -3.4% | -11.9% | -18.0% | |
| Q2 2025 | +0.4% | +8.4% | -24.0% | |
| Q1 2025 | -3.1% | -5.1% | -68.7% | |
| Q4 2024 | -4.0% | -7.9% | -25.4% | |
| Q3 2024 | +6.6% | -0.6% | -28.2% | |
| Q2 2024 | -14.3% | -30.2% | -46.4% | |
| Q1 2024 | +51.9% | +47.1% | +29.4% | |
| Q4 2023 | -20.7% | -18.3% | -36.7% | |
| Q3 2023 | -10.0% | -12.9% | -14.3% | |
| Q2 2023 | -5.1% | -3.0% | -22.2% | |
| Q1 2023 | -29.9% | -37.8% | -34.6% | |
| Q4 2022 | -5.1% | -6.5% | -41.2% | |
| Q3 2022 | -19.6% | -16.7% | -50.0% | |
| Q2 2022 | -6.5% | -4.2% | +23.9% | |
| Q1 2022 | +1.0% | +2.9% | -7.4% | |
| Q4 2021 | -1.2% | -6.1% | +2.0% | |
| Q3 2021 | -17.0% | -13.2% | -33.3% | |
| Q2 2021 | +9.6% | +7.9% | +3.0% | |
| Q1 2021 | -14.6% | -8.9% | +6.6% | |
| Q4 2020 | +5.7% | -6.2% | -21.3% | |
| Q3 2020 | -7.8% | -7.0% | +14.1% | |
| Q2 2020 | -16.0% | -32.0% | -68.0% | |
| Q1 2020 | -9.6% | -14.6% | +2.4% | |
| Q4 2019 | -28.8% | -33.9% | -29.0% | |
| Q3 2019 | -15.0% | -23.0% | -16.0% | |
| Q2 2019 | -1.2% | +2.0% | +0.4% | |
| Q1 2019 | -13.3% | -13.3% | -24.9% | |
| Q4 2018 | -12.6% | -25.6% | -69.8% | |
| Q3 2018 | +2.8% | +4.7% | -21.7% | |
| Q2 2018 | -26.4% | -37.4% | -23.9% | |
| Q1 2018 | -17.1% | -18.8% | -23.3% | |
| Q4 2017 | -15.5% | -25.7% | -21.0% | |
| Q3 2017 | -12.8% | -15.6% | -47.3% | |
| Q2 2017 | -4.0% | -13.3% | -6.7% | |
| Q1 2017 | -9.5% | -1.4% | -9.5% | |
| Q4 2016 | -5.3% | -12.0% | -58.0% | |
| Q3 2016 | -5.0% | -5.0% | +190.0% | |
| Q2 2016 | -14.9% | -16.0% | -17.0% | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -15.9% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -3.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -17.5% | — | — | |
| Q2 2014 | +23.9% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | +2.1% | — | — | |
| Q1 2013 | +6.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q2 2012 | -7.6% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro